ImmunoTea Episode 1 - IL-17 and Neurological Autoimmunity
Jan 9, 2023
auto_awesome
In this fascinating discussion, distinguished immunologist Prof. Kingston Mills and neurological autoimmunity expert Dr. Anastasia Zekeridou dive deep into the powerful cytokine IL-17. They unpack its dual role in diseases like multiple sclerosis, emphasizing targeted therapies and potential risks of blocking IL-17. The guests also touch on the role of tissue-resident memory T cells and the implications of immune responses in paraneoplastic neurological syndromes. Their insights on antibody pathogenicity and the intersection of cancer treatment with neurological autoimmunity are truly enlightening.
IL-17 is a crucial cytokine in both immune response and autoimmune pathology, acting as a double-edged sword in various diseases.
The interplay between cancer treatments and neurological autoimmunity underscores the need for predictive models to identify at-risk patients.
Deep dives
Understanding Interleukin 17's Dual Role
Interleukin 17 (IL-17) functions as both a protective and damaging cytokine, making it a significant focus in immunology research. Originally identified in multiple sclerosis patients, IL-17 is crucial for the immune response to fungal and bacterial infections, yet it also mediates pathology in various autoimmune diseases. The cytokine acts similarly to a double-edged sword, contributing to inflammation in conditions like psoriasis and ankylosing spondylitis while playing a protective role against infections. Recent studies underscore IL-17's potential as a therapeutic target, with several therapies now in use that specifically target IL-17 to treat autoimmune diseases.
Therapeutic Potential and Challenges of Targeting IL-17
The clinical applicability of targeting IL-17 in treatments varies based on the disease context, posing both opportunities and challenges. In conditions like psoriasis and psoriatic arthritis, therapies targeting IL-17 have shown effectiveness; however, the results in diseases such as Crohn's disease have been unexpectedly counterproductive, leading to worsened patient outcomes. The pathophysiology is complex, as IL-17 also plays a role in maintaining gut flora. Ongoing research aims to understand these discrepancies better, emphasizing the need for stratified approaches to treatment based on patient-specific mechanisms.
The Intersection of Cancer and Neurological Autoimmunity
Paraneoplastic neurological syndromes (PNS) occur when the immune response against tumors inadvertently targets the nervous system, leading to various neurological manifestations. These rare conditions can arise from cancer antigens that resemble neural antigens, prompting autoimmune responses that may coincide with better cancer prognosis. The advent of checkpoint inhibitors in cancer treatment has raised awareness of PNS, as these therapies can exacerbate pre-existing neurological issues or trigger new autoimmune responses. Understanding the nuanced relationship between cancer treatments and neurological health is critical as checkpoint inhibitors become increasingly common in oncological practice.
Future Directions in Autoimmunity and Immune Checkpoint Inhibitors
There is a growing need to predict which patients may develop neurological complications from immune checkpoint inhibitors, as such adverse reactions can complicate treatment strategies. Research indicates that pre-existing neural antibodies in asymptomatic patients may heighten the risk of immune-related neurological events upon receiving these therapies. The main focus going forward will be on developing predictive models to identify at-risk patients, thus enabling tailored monitoring and interventions. This individualized approach may significantly improve patient outcomes while navigating the complexities of treating both cancer and neurological autoimmunity.
On this episode Lara and Vyanka talk to Prof Kingston Mills and Dr Anastasia Zekeridou all about IL-17 and and neurological autoimmunity. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter.